Highest-materiality recent filing
Bausch Health files 8-K for Q2 2026 results; press release not included in provided text
Filing indicates results of operations for Q2 2026 were announced on July 29, 2026.
Director Michael Goettler resigns from Bausch Health board to become CEO of Knoa Pharma
Resignation effective June 30, 2026, due to appointment as President and CEO of Knoa Pharma LLC.
Bausch Health elects Eiry W. Roberts as new director; say-on-pay passes at annual meeting
Eiry W. Roberts elected to board with 196,972,752 votes for, 2,585,679 withheld; broker non-votes 79,859,606.
Bausch Health reports Q1 2026 results; detailed figures not available in excerpt
Filing references earnings press release for quarter ended March 31, 2026, issued April 29, 2026.
Bausch Health changes CEO and EVP PSU settlement from stock to cash for 2023 awards
1,137,862 PSUs for CEO Thomas Appio amended to cash settlement instead of stock upon March 3, 2026 vesting.
Bausch Health reports Q4/FY2025 results; press release content not available in filing excerpt
Quarterly earnings release furnished under Item 2.02; no specific financial data provided in this excerpt.
Bausch Health issues press release on Phase 3 RED-C trial; no details in filing text
Press release announces results of global Phase 3 RED-C program for amorphous-rifaximin in liver cirrhosis.
Bausch Health to reaffirm FY2025 guidance at high end at JPM conference
Presentation at 44th Annual J.P. Morgan Healthcare Conference on Jan 14, 2026 at 3:45 p.m. PT.
Bausch + Lomb closes $2.8B term loan refinancing, reduces margins, extends maturity
Closed $2.802B Replacement Term Loans maturing 2031 to refinance existing term B loans due 2028 and 2031.
Issued $1.6B aggregate principal of new 10.00% Senior Secured Notes due 2032 in exchange for outstanding 4.875% and 11.00% notes due 2028.
Bausch Health completes debt exchange for up to $1.6B in 10.00% senior secured notes due 2032
Exchange offers expired Dec. 23, 2025; old 4.875% and 11.00% senior secured notes due 2028 exchanged for new notes.
Bausch + Lomb refinances $2.8B term loans; margin cut, maturity extended to 2031
$2.802B new Replacement Term Loans to refinance existing term B loans due 2028 and 2031.
Bausch Health announces early results of debt exchange offers; press release details not provided
Company offered to exchange outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for up to $1.6B new 10.00% Senior Secured Notes due 2032.
Bausch Health launches exchange of up to $1.6B notes, offers 10% senior secured notes due 2032
Offers to exchange 4.875% and 11.00% Senior Secured Notes due 2028 for new 10.00% Senior Secured Notes due 2032; up to $1.6B aggregate principal.
Bausch Health announces Q3 2025 results; exhibit with details not provided
Press release for Q3 ended September 30, 2025 issued on October 29, 2025.
Bausch Health shareholders approve Amended and Restated Rights Plan at special meeting
Special meeting held Oct 7, 2025; shareholders voted to ratify the Rights Plan Agreement.
Bausch Health completes acquisition of DURECT for $1.75/share plus CVRs
Tender offer closed with 62% of DURECT shares (19.98M) validly tendered and accepted.
Brett M. Icahn and Steven D. Miller resigned from the board effective August 14, 2025, upon termination of the Director Appointment and Nomination Agreement.
Bausch Health files Q2 2025 earnings release; financial figures not included in provided text
Press release issued July 30, 2025 for quarter ended June 30, 2025.
Bausch Health to acquire DURECT for $1.75/share ($63M upfront) plus up to $350M milestones
Bausch Health will pay $1.75/share cash upfront, valuing DURECT at ~$63M, with up to $350M in additional net sales milestone payments.
Bausch Health appoints Michael Goettler and Sandra Leung to Board, effective July 22, 2025
Board expands from 10 to 12 members with the addition of two new directors.
Bausch Health appoints Steven Lee as SVP, Controller and Chief Accounting Officer
Effective July 14, 2025; Lee will oversee financial reporting and corporate controllership.
Bausch + Lomb closes upsized €675M senior secured notes and $2.325B term loan refinancing
Issued €675M senior secured floating rate notes due 2031 at 3-month EURIBOR+3.875%.
Bausch + Lomb prices €675M secured notes, upsized; new term loan $2.325B
Priced €675M senior secured floating rate notes due 2031 at 99.5% of principal; offering upsized from €600M.
Bausch + Lomb launches €600M senior secured notes offering and $2.2B term loan refinancing
Subsidiaries launch €600M senior secured floating rate notes.
Bausch Health enters standstill-like pacts with Icahn, Paulson, Kavanagh limiting activism
Icahn Group, John Paulson, and Sarah Kavanagh each signed letter agreements with Bausch Health on May 20, 2025.
Bausch Health CAO John Barresi resigns, effective June 2; CFO Charhon to serve as interim CAO
John S. Barresi resigns as SVP, Controller and CAO effective June 2, 2025.
Bausch Health shareholders reelect all 10 directors, approve say-on-pay and ESPP at May 13 AGM
All 10 director nominees elected with over 199 million votes for each; broker non-votes ~56.3M.
Bausch Health Q1 2025 earnings release filed; figures not available in excerpt
Q1 2025 results announced via press release; financial data not included in the provided text.
Bausch Health adopts shareholder rights plan (poison pill) effective April 14, 2025
Board approved shareholder rights plan on April 14, 2025; one right attaches to each common share outstanding.
Bausch Health closes $4.4B 10% secured notes due 2032 and $3B term loan facility
Closed offering of $4.4B aggregate principal of 10.000% senior secured notes due 2032 via subsidiary 1261229 B.C. Ltd.
Bausch Health prices $4.4B 10% senior secured notes due 2032, upsized from $4.0B
Bausch Health priced $4.4B aggregate principal of 10.000% senior secured notes due 2032, upsized from $4.0B.
Bausch Health launches $4.0B secured notes offering and $3.8B credit facilities to refinance debt
Indirect subsidiary launched $4.0B senior secured notes due 2032 to qualified institutional investors.
Bausch Health reports Q4/FY2024 results but filing lacks specific financial figures
Filed an 8-K on Feb 19, 2025, announcing Q4 and full year 2024 results via press release.
Bausch + Lomb borrows $400M in new term loans maturing May 2027
Bausch + Lomb added $400M term loans under its credit agreement; proceeds used to repay revolver and for corporate purposes.
Bausch Health Q3 2024 results announced; no specific figures in filing
Press release attached as Exhibit 99.1 was not included in provided text.
Bausch Health issues Q2 2024 earnings press release; details not available
Form 8-K filed August 1, 2024, referencing press release as Exhibit 99.1.
Bausch Health appoints Jean-Jacques Charhon as CFO, Aimee Lenar as EVP US Pharma
Jean-Jacques Charhon named CFO effective Aug 19, 2024; base salary $700K, target bonus 60%, equity grants ~$3M.
All nine director nominees elected; each received over 170M votes for, with ~70.9M broker non-votes.
Bausch Health releases Q1 2024 earnings; no financial details available
Press release issued on May 2, 2024 for quarter ended March 31, 2024.
Bausch Health reports Q4/FY 2023 results; exhibit with details not provided
Item 2.02 announces earnings release for quarter and year ended Dec 31, 2023.
Bausch Health board members Robertson and Ross to retire, not stand for re-election
Russel C. Robertson and Thomas W. Ross, Sr. notified they will not stand for re-election at 2024 annual meeting.
Bausch Health's B+L closes $1.75B acquisition of XIIDRA from Novartis; issues $1.9B in debt
Bausch + Lomb acquired XIIDRA and other ophthalmology assets from Novartis for $1.75B upfront cash plus up to $750M in milestone payments.
Bausch Health reports Q3 2023 results; specific figures not available in submitted text
Press release issued on Nov 2, 2023 for quarter ended Sep 30, 2023.
Bausch Health discloses interim CFO John Barresi's compensation terms
Bi-weekly cash stipend of $5,000 added to base pay during interim CFO service.
Bausch + Lomb completes $2.5B XIIDRA acquisition from Novartis, funded with $1.9B debt
Upfront $1.75B cash plus up to $750M milestone for XIIDRA and other ophthalmology assets from Novartis.
Bausch Health CFO Tom Vadaketh resigns; John Barresi to serve as interim CFO if needed
Tom Vadaketh resigns as CFO effective Oct 13, 2023 to pursue another opportunity; no disagreement with company.
Bausch + Lomb subsidiary prices $1.4B 8.375% senior secured notes due 2028
Bausch + Lomb subsidiary Bausch + Lomb Escrow Corp. priced $1.4B of 8.375% senior secured notes due 2028.
Bausch + Lomb launches $1.4B notes offering and $500M term loan for XIIDRA acquisition
Bausch + Lomb Escrow Corp. launched $1.4B senior secured notes due 2028; Bausch + Lomb seeks $500M incremental term B loan.
Bausch + Lomb provides financial details for planned acquisition of Novartis eye-care assets
Deal: $1.75B upfront plus up to $750M milestones for Xiidra, AcuStream, SAF312, OJL332.
On June 26, 2026, Mr. Michael Goettler notified Bausch Health Companies Inc. (the “Company”) of his decision to resign from the Board of Directors (the “Board”), effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.
until a permanent replacement is in place, at the time that Mr. Barresi ceases to be the Chief Accounting Officer, Jean-Jacques Charhon, who is currently serving as the Company’s Executive Vice President and Chief Financial Officer, will assume the additional role of Chief Accounting Officer.
On May 9, 2025, John S. Barresi informed Bausch Health Companies Inc. (the “Company”) of his decision to resign as the Senior Vice President, Controller and Chief Accounting Officer of the Company.
John S. Barresi, who has served as the Company’s interim Chief Financial Officer since October 2023, will no longer act in this capacity and will continue in his role as Senior Vice President, Controller and Chief Accounting Officer.
On July 15, 2024, the Board of Directors (the “Board”) of Bausch Health Companies Inc. (the “Company”) appointed Jean-Jacques Charhon as the Company’s Executive Vice President and Chief Financial Officer, effective as of August 19, 2024.
On January 29, 2024, Mr. Russel C. Robertson and Mr. Thomas W. Ross, Sr. each notified Bausch Health Companies Inc. (the “Company”) of their decision not to stand for re-election at the Company’s 2024 annual meeting of shareholders.
On January 29, 2024, Mr. Russel C. Robertson and Mr. Thomas W. Ross, Sr. each notified Bausch Health Companies Inc. (the “Company”) of their decision not to stand for re-election at the Company’s 2024 annual meeting of shareholders.
Tom Vadaketh informed Bausch Health Companies Inc. (the “Company”) of his decision to resign as the Executive Vice President, Chief Financial Officer of the Company.
John S. Barresi, who is currently serving as the Company’s Senior Vice President, Controller and Chief Accounting Officer, will assume the additional role of interim Chief Financial Officer.
On February 28, 2023, Mr. Richard De Schutter and Dr. Argeris Karabelas notified Bausch Health Companies Inc. (the “Company”) of their decision to retire as directors from the Board of Directors (the “Board”) of the Company, effective at the upcoming 2023 annual meeting of shareholders of the Company (the “2023 Annual Meeting”).
On February 28, 2023, Mr. Richard De Schutter and Dr. Argeris Karabelas notified Bausch Health Companies Inc. (the “Company”) of their decision to retire as directors from the Board of Directors (the “Board”) of the Company, effective at the upcoming 2023 annual meeting of shareholders of the Company (the “2023 Annual Meeting”).
Also on June 23, 2022, the Company announced the Board’s appointment of John A. Paulson to the Board to fill the resulting vacancy, effective upon Mr. Papa’s resignation.
Max materiality 0.85 · Median 0.53 · Most common event debt